2025-06-14-Jefferies-因塞特公司（INCY）_mCALR在原发性血小板增多症（ET）中明显有效_并将于2026年初启动关键研究；年底前公布骨髓纤维化（MF）数据_12页_3mb

报告摘要

Incyte is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutics. It operates in two therapeutic areas: Hematology/Oncology (focusing on Myeloproliferative Neoplasms, GvHD, and solid tumors) and Inflammation/Autoimmunity (including Dermatology with products like Opzelura).

Rating: BUY, with a price target of $82.00 (+21% from current price $67.75).
Stock Performance: Current 52-week high was $83.95, low was $53.56.
Market Capitalization: $13.4B.
Revenue/Profit Projections: Analysts project growth driven by key assets, with EPS data showing positive outlook.

Core Assets: Incyte's best-selling drug, Jakafi, is set to face a revenue dip due to loss of exclusivity (LOE) in 2028, but the company's strategy focuses on mitigating this through diversification.
- Diversification into dermatology includes Opzelura (targeting AD and vitiligo with $1.9B peak sales) and Povorcitinib ( oral JAK inhibitor for HS and vitiligo with $1.3B risk-adjusted peak sales).
- The mCALR-targeting mAb INCA033989 is advancing in Phase 1 trials, aiming for ET and MF indications with potential peak sales of $358M.
Key Drivers: Jakafi's performance, dermatology franchise growth, and mCALR program create upside potential by broadening revenue streams.

Development Risks: Clinical trial failures, regulatory hurdles, commercial delays, and competitive pressures from JAK inhibitors and other therapies.
Business Risks: Manufacturing issues, pricing challenges, and market access concerns.

Price Target: $82.00, driven by a discounted cash flow (DCF) model assuming a WACC of 9.5%, terminal growth rate of -1%, and 198 million shares outstanding.
Assumptions: Sales of Jakafi, Opzelura, and Povorcitinib are key inputs; early-stage assets are not included in the model but represent future upside.

Recent mCALR Data: Phase 1 ET data show significant biological activity, including VAF reduction and platelet normalization, with promising results compared to benchmarks. ET pivotal trial is planned for early 2026; MF data expected by year-end.
Other Programs: A mCALR x CD3 bispecific antibody is in early Phase 1 development, potentially targeting non-responders.
Financial Projections: Revenue growth is expected, with Jakafi sales stabilizing post-LOE, while dermatology assets could drive higher revenues by 2035.

Positive clinical data for mCALR and Povorcitinib, regulatory approvals, commercial uptake of new products, and successful management of LOE for Jakafi.

展开完整摘要